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Schizophrenia is a brain disorder associated with cognitive deﬁcits that severely aﬀect the patients’ capacity for daily functioning.
Whereas our understanding of its pathophysiology is limited, postmortem studies suggest that schizophrenia is associated with
deﬁcits of GABA-mediated synaptic transmission. A major role of GABA-mediated transmission may be producing synchronized
network oscillations which are currently hypothesized to be essential for normal cognitive function. Therefore, cognitive deﬁcits
in schizophrenia may result from a GABA synapse dysfunction that disturbs neural synchrony. Here, we highlight recent studies
further suggesting alterations of GABA transmission and network oscillations in schizophrenia. We also review current models for
the mechanisms of GABA-mediated synchronization of neural activity, focusing on parvalbumin-positive GABA neurons, which
are altered in schizophrenia and whose function has been strongly linked to the production of neural synchrony. Alterations
of GABA signaling that impair gamma oscillations and, as a result, cognitive function suggest paths for novel therapeutic
interventions.
1.Introduction
Schizophrenia is a severe brain disorder that aﬄicts 0.5–
1% of the world’s population and that is typically ﬁrst
diagnosed in late adolescence or early adulthood. The
illness is manifest as disturbances in perception, attention,
volition, inferential thinking, ﬂuency and production of
language,andtherecognitionandexpressionofemotionthat
lead to substantial impairments in social and occupational
functioning.Manyaﬀectedindividualssuﬀerfromcomorbid
depression, an increased risk of cardiovascular disease, and
excessive nicotine, alcohol, and cannabis use.
Threemajordomains ofsymptomsdeﬁneschizophrenia.
The ﬁrst domain is positive or psychotic symptoms that
include delusions, false beliefs ﬁrmly held in the face of
contradictory evidence; perceptual disturbances and hallu-
cinations, which may occur in any sensory modality but are
most commonly auditory and experienced as hearing voices
distinct from one’s own thoughts; abnormalities in form of
thought that are usually manifest as loose associations, over-
inclusiveness, and/or neologisms; abnormal psychomotor
activity that is usually manifest as grossly disorganized
behavior, posturing, and/or catatonia. Negative symptoms
include asociality (withdrawal or isolation from family
and friends), avolition (impaired initiative, motivation, and
decision-making), alogia (poverty in the amount or content
of speech), and anhedonia (reduced capacity to experience
pleasure). The third category of symptoms includes a
number of cognitive abnormalities such as disturbances
in selective attention, working memory, executive control,
episodic memory, language comprehension, and social-
emotional processing.
Although positive symptoms are usually the presenting
and most striking clinical feature of schizophrenia, distur-
bances in cognition appear to be the core features of the
illness as they are present before the onset of psychosis and
are the best predictor of long-term functional outcome for
schizophrenia patients [1]. Therefore, functional recovery
(e.g., recovery of the capacity to maintain employment) is
largely dependent on improving cognitive deﬁcits.
Although schizophrenia was initially characterized over
100 years ago, we still haveonly a limited understanding2 Neural Plasticity
of its pathophysiology. Moreover, we lack eﬃcient tools for
its treatment or prevention. For example, the multicenter,
NIMH-funded Clinical Antipsychotic Trials in Interven-
tion Eﬀectiveness project recently found that newer atyp-
ical antipsychotics are not signiﬁcantly more eﬀective for
treating psychosis than older typical antipsychotic medi-
cations and showed little beneﬁt for improving cognitive
symptoms [2, 3]. These ﬁndings highlight the need to
develop novel therapeutic interventions for schizophrenia
[4, 5].
If functional recovery of patients with schizophrenia
depends on improving cognitive deﬁcits, then understand-
ing the neural basis of the normal cognitive operations
that are impaired in schizophrenia is crucial to develop
new therapies. Interestingly, a number of ﬁndings from
postmortem brain studies suggest that schizophrenia is
associated with deﬁcits of GABA-mediated synaptic trans-
mission [6]. Furthermore, current hypotheses from cellular
and systems neurophysiology suggest that a major role of
GABA-mediated transmission is to produce synchronized
neural network oscillations [7, 8] which by facilitating the
processing and ﬂow of information within and between
brain regions may be essential for normal cognitive function
[9]. Here we review convergent ﬁndings from schizophrenia
research, cellular neurophysiology, and cognitive neuro-
science that favor the hypothesis that deﬁcits of cognitive
function in schizophrenia result from a dysfunction in
GABA-mediated synaptic inhibition that disturbs oscillatory
neural synchrony.
This paper reviews recent evidence further indicating
that in subjects with schizophrenia cognitive dysfunction
is associated with alterations of oscillations in the gamma
frequency band (30–80Hz), which are normally induced
during tasks that engage cognition [10]. In addition, it
reviews the cellular and molecular machinery involved
in GABA-mediated synaptic transmission and the mecha-
nisms by which GABA-mediated inhibition may synchronize
neural activity in cortical circuits, focusing on the role
of parvalbumin- (PV-) positive GABA neurons, whose
function has been increasingly linked to the production
of synchronized gamma oscillations. Furthermore, data on
the postnatal development of PV GABA neurons and their
synaptic connections and the developmental trajectories of
gene products involved in GABA-mediated synaptic inhibi-
tion is reviewed. Finally, recent studies further suggesting
that schizophrenia is associated with alterations in GABA-
mediated synaptic transmission, particularly, but not exclu-
sively,fromPVneuronsarehighlighted.AlterationsofGABA
signaling that impair gamma oscillations and therefore
cognitive function in schizophrenia suggest potential paths
for therapeutic interventions.
2. Altered Neural Synchrony and Cognitive
Function in Schizophrenia
Schizophrenia is associated with deﬁcits in behavioral tasks
that assess perceptual and cognitive processes [10, 11].
Many such tasks normally increase synchronized oscillatory
activity as measured in the electroencephalogram (EEG),
a n ds u c hi n c r e a s ei ns y n c h r o n yi sa l t e r e di ns u b j e c t s
with schizophrenia [11, 12]. For example, gamma-band
synchrony during tasks that require visual gestalt perception
is attenuated in schizophrenia patients [13]. One of the
core cognitive deﬁcits in schizophrenia is a dysfunction of
working memory, a system to keep information in mind
and to manipulate it while performing complex tasks [14].
Gamma oscillatory activity (30–80Hz) may play an impor-
tantroleinnormalworkingmemory,giventhatgammaband
synchrony increases with increasing working memory load
[15, 16]. In patients with schizophrenia, working memory
deﬁcits are accompanied by altered patterns of cortical
oscillatory activity [11], since schizophrenia patients actually
fail to enhance gamma activity with increasing working
memory load [16] and show overall increased gamma band
power during working memory [16, 17]. Subjects with
schizophrenia also have decreased oscillations in various
frequency bands during speciﬁc phases of the working mem-
ory process, including encoding, maintenance, and retrieval
[18].
Cognitive function, including working memory, impli-
cates an interconnected network of brain regions, many
of which show structural and functional abnormalities in
schizophrenia [19]. The prefrontal cortex (PFC), which
is extensively interconnected with cortical and subcortical
regions, is thought to exert top-down control of the ﬂow
of neural activity between brain regions to provide cog-
nitive control, coordinating incoming sensory and motor
information with representations of internal goals and
rules to select a context-appropriate behavioral response
[20]. Subjects with schizophrenia have signiﬁcant deﬁcits in
cognitive control [10] and attenuated gamma oscillations in
PFC during cognitive control tasks [21]. Cognitive control-
related gamma activity, but not theta activity, is reduced
in the frontal cortex of ﬁrst-episode schizophrenia patients
independentofmedicationstatus,suggestingadeﬁcitrelated
tothediseaseprocessasopposedtomedicationsideeﬀectsor
the consequences of being chronically ill [22]. Interestingly,
some studies reported a positive correlation between gamma
oscillationsandhallucinationsymptomsscoreinschizophre-
nia[23,24],indicatingthatthepropensityforauditoryhallu-
cinationscorrelateswithanincreasedtendencytoenterstates
of oscillatory synchrony [24]. It remains to be determined
whether the decrease in gamma activity associated with cog-
nitive deﬁcits and the positive correlation between gamma
activity and psychotic symptoms are due to diﬀerent under-
lyingmechanisms,mannersofelicitinggamma,orcohortsof
subjects.
If, as suggested by multiple lines of evidence, altered
neural synchrony underlies impairment of cognition in
schizophrenia, then understanding the neural mechanisms
normally involved in production of synchronized oscil-
lations in neocortical circuits is crucial to develop new
therapeutic interventions. Whereas several mechanisms have
been proposed, production of rhythms via GABA-mediated
inhibition is currently a leading candidate mechanism, as
reviewed in the following.Neural Plasticity 3
3.BasicMechanismsofGABA-MediatedFast
SynapticTransmission
By deﬁnition, GABA neurons have the capacity to synthe-
size GABA from glutamate via the enzymatic activity of
glutamic acid decarboxylase (GAD), for which there are
two gene products of diﬀerent molecular weight, GAD65
and GAD67 [25]. Whereas the GAD isoforms diﬀer in a
number of properties, their speciﬁc functional roles are not
fully understood [25]. Interestingly, GAD65 and GAD67 are
diﬀerentiallyexpressedinGABAergicterminalsinacelltype-
speciﬁc manner (see below).
GAD-mediated GABA synthesis occurs in the cytosol,
and GABA is transported into synaptic vesicles by the
vesicular GABA transporter vGAT (Figure 1). Shortly after
an action potential arrives at the nerve terminal, vesicular
GABA release is triggered with a certain probability and
in a Ca2+-dependent manner. In PV neuron terminals, PV
may act as a Ca2+ buﬀer that binds residual Ca2+ after
activation of the Ca2+ sensor that triggers vesicular GABA
release. At all synaptic connections from cortical GABA
neurons thus far studied, the eﬀects of synaptically released
GABA are mediated by GABAA receptors (GABAARs), as the
postsynaptic response is abolished by GABAAR antagonists
in hippocampus [26–33] and neocortex [34–41]. In contrast,
GABAB receptors mediate the postsynaptic eﬀects of GABA
only at connections from GABA neurons of the neurogli-
aform cell subtype [42].
Postsynaptic GABAARs are heteropentamers composed
of subunits from 7 diﬀerent families (α1−6, β1−3, γ1−3, δ, ε,
θ,a n dρ1−3) typically combined following a 2α:2β:γ stoi-
chiometry to form a GABA-activated chloride channel [43,
44]. Importantly, the subunit composition of the GABAAR
complex determines many of its functional properties. For
instance, GABA-activated chloride currents produced by α1
subunit-containing GABAARs (α1-GABAARs) have much
faster decay kinetics than currents mediated by GABAARs
containing other α subunits [43].
The subunit composition also determines important
pharmacological properties of the GABAARs. Benzodi-
azepines bind to GABAARs via a binding site localized
at the interface between α and γ subunits [45, 46]a n d
may modulate (potentiate or decrease) GABAARf u n c t i o n
in an α subunit-selective manner [47]. For example, zolpi-
dem enhances GABA eﬀects preferentially at α1-GABAARs,
whereas the α3IA and α5IA compounds are inverse agonists
preferentially at α3-GABAARs and α5-GABAARs, respec-
tively [47]. Other drugs, including TPA023 (also named
MK0777), TPA023B, TPA123, and TPA003 have comparable
binding aﬃnity at α1-, α2-, α3-, and α5-GABAARs but may
lack pharmacological eﬀects at certain GABAARs u b t y p e s .
In particular, TPA023 is a partial agonist at α2- and α3-
GABAARs but has no agonist eﬃcacy at α1- and α5-
GABAARs [48].
Themagnitudeanddirectionoftheioniccurrentﬂowing
through GABAARs depends on its driving force or diﬀerence
between its electrochemical equilibrium potential (EGABAA)
and the resting membrane potential (Vmr) in the plasma
membrane compartment where GABAARs are located [49].
BecauseGABAARchannelsarelargelypermeabletochloride,
EGABAA is close to the chloride equilibrium potential (ECl)
and therefore EGABAA depends on the sodium-potassium-
chloride cotransporter 1 (NKCC1) and the potassium-
chloride co-transporter 2 (KCC2), which mediate chloride
uptake and extrusion, respectively [43]. Importantly, since
the active GABAAR conductance tends to “clamp” the mem-
brane potential at EGABAA [49], if EGABAA is negative relative
to Vmr (Vmr >E GABAA), the GABAAR currents are hyperpo-
larizing, whereas if EGABAA is positive to Vmr (EGABAA >V mr),
the GABAAR currents produce depolarization. Commonly,
EGABAA is negative to Vmr,h o w e v e r ,i nc e r t a i nc e l lt y p e so r
subcellular compartments (and in general, early in brain
development) EGABAA >V mr [43].
Whether the GABAAR conductance has inhibitory or
excitatory eﬀects depends on the relation between EGABAA
and the voltage threshold for action potential ﬁring (Vth),
which is always depolarized relative to Vmr (Vth >V mr).
When Vth >V mr >E GABAA, the chloride current is
hyperpolarizing and clearly inhibitory because it shifts
the membrane potential away from ﬁring threshold, thus
reducing the probability of ﬁring. In contrast, if EGABAA >
Vth >V mr, the chloride current is excitatory because it
tends to depolarize the membrane above Vth.H o w e v e r ,i f
Vth >E GABAA >V mr, the GABAAR conductance is inhibitory
because, even though EGABAA >V mr, shunting by the active
GABAAR conductance keeps the membrane potential below
ﬁringthreshold.Importantly,GABAAR-mediatedinputsthat
depolarize the membrane below Vth (Vth >E GABAA >V mr)
can have dual, time-dependent inhibitory/excitatory eﬀects.
Initially, when the GABAAR conductance is active, the net
eﬀect of the synaptic input is inhibitory because of the
shunting eﬀect [50]. However, the depolarizing postsynaptic
potential outlasts the duration of the GABAARc o n d u c t a n c e ,
thus increasing the ﬁring probability once the GABAAR
conductance decays [50]. Importantly, the depolarizing
GABAAR-mediatedpost-synapticpotentialmaybeampliﬁed
by voltage-dependent Na+ currents localized perisomatically,
possiblyintheinitialsegmentoftheaxon[51,52],enhancing
its excitatory eﬀect. The inhibitory versus excitatory eﬀect
of the GABAAR conductance may be dynamic, because Vmr
and Vth are subject to modulation and change over time. In
addition, EGABAA m a yv a ryb e t w e e nc e l ltyp e sa n ds u b c e l l u l a r
compartments, depending on the NKCC1/KCC2 activity
ratio [43].
It has been commonly suggested that uptake of extra-
cellular GABA by plasma membrane transporters could
help terminate the synaptic eﬀect of GABA and thus the
duration of the inhibitory postsynaptic current (IPSC). In
the CNS, GABA uptake is largely mediated by the plasma
membrane GABA transporter 1 (GAT1) which translocates
GABA through the neuronal and glial membrane (Figure 1).
Interestingly, recent experiments indicate that GAT1 does
not control the time course of GABAAR-mediated IPSCs,
since the duration of IPSCs produced at single synapses is
not aﬀected by pharmacological inhibition of GAT1, nor
in GAT1 knockout mice [53–56]. The ﬁnding that GAT1
does not control IPSC duration may be explained by GAT1’s
predominantly extrasynaptic localization [57–62]a n db y4 Neural Plasticity
GABA
nerve
terminal
PV
Glutamate
GAD67
GAD65
vGAT
Sensor
GAT1
Glia
NKCC1
KCC2
Synaptic
Extra-synaptic
GABA
C1−
Ca2+
GABAARs
GABAARs
Figure 1: Scheme showing a nerve terminal from a parvalbumin- (PV-) positive GABA neuron shortly after an action potential triggered
Ca2+-dependent GABA release, highlighting components currently hypothesized to be altered in schizophrenia. In PV terminals, GABA
release is tightly synchronized with Ca2+ inﬂux, possibly due to the proximity between voltage-dependent Ca2+ channels and release sites.
PV is a relatively slow buﬀer that probably is unable to bind Ca2+ before activation of the Ca2+ sensor promotes vesicle fusion. Ca2+ buﬀering
by PV mainly accelerates the decay of the intraterminal Ca2+ transient (see text). GAD65 and GAD67, possibly acting as a dimer, drive
GABA synthesis in the cytosol near synaptic vesicles. Vesicles uptake newly synthesized GABA via the vesicular GABA transporter vGAT.
Vesicle fusion rapidly and transiently raises GABA concentration in the synaptic cleft, brieﬂy exposing post-synaptic GABAA receptors
(GABAARs) to a high concentration of GABA. As GABA escapes from the synaptic cleft after GABAAR activation, it may be taken up by the
plasma membrane GABA transporter GAT1, apparently localized in the extrasynaptic neuronal membrane, as well as in glia. GAT1 therefore
regulates the concentration of GABA reaching extrasynaptic GABAARs and synaptic GABAARs at other synapses (not shown in the scheme).
The direction and magnitude of the chloride current produced by postsynaptic GABAAR activation is regulated by the transporters KCC2
and NKCC1, which uptake and extrude chloride, respectively, setting the equilibrium potential for the GABAA current, EGABAA. Since PV
acceleratesthedecayoftheintraterminalCa2+ transients,adecreaseofPVinschizophreniamayfacilitaterepetitiveGABArelease,suchasthat
observed during gamma oscillation episodes. A decrease of GAD67 levels in schizophrenia would reduce the cytosolic GABA concentration
near synaptic vesicles. Because vGAT levels appear to be unaﬀected in schizophrenia, reduced GAD67 may lead to lower intravesicular
GABA concentration, therefore decreasing the peak GABA concentration in the synaptic cleft and weakening the postsynaptic response. In
schizophrenia, at some synapses postsynaptic GABAAR density appears to be decreased, further weakening synaptic transmission, whereas
at other synapses GABAAR density is increased, possibly due to compensatory receptor upregulation. In schizophrenia, KCC2 and NKCC1
mRNA levels are normal, but two kinases that strongly regulate KCC2 and NKCC1 may be altered in ways that render an EGABAA value more
depolarizing than normal. Finally, reduced GAT1 in schizophrenia may alter the eﬀects of synaptically released GABA via an exaggerated
activation of extrasynaptic and heterosynaptic GABAARs. Alternatively, GAT1 activity may be reduced to compensate lower GABA levels due
to GAD67 deﬁciency.
the slow GAT1-mediated GABA translocation rate [63, 64]
compared with the rapid GABAAR activation by synaptic
GABA [43]. Other experiments suggest that GAT1’s main
role is preventing intersynaptic GABA spillover [53, 56],
(e.g., the unintended activation of GABAARs at a given
synapse by GABA released at adjacent synapses). Four
diﬀerent GABA transporters have been cloned: GAT1,
GAT2, GAT3, and BGT1 [65]; therefore, it is possible
that some of the GABA transporters diﬀerent from GAT1
have properties consistent with uptake-mediated control
of IPSC duration. However, GAT2 is only found during
very early brain development and BGT1 is not abundant
in brain [65]. GAT3 is mostly localized in glia, and the
eﬀects of GAT3 blockade indicate that, similar to GAT1,
GAT3’s main role is reducing the eﬀects of GABA spillover
[66].Neural Plasticity 5
4. Mechanisms of GABAAR-Mediated-Gamma-
Band Synchronization
The mechanisms by which GABAAR-mediated inhibi-
tion may synchronize postsynaptic cell activity have been
reviewed in detail previously [7, 8, 67, 68]. Figure 2 illus-
trates a group of pyramidal neurons ﬁring asynchronously
in response to some excitatory inputs that receive com-
mon GABAAR-mediated hyperpolarizing inhibition. If such
GABA-mediated hyperpolarizing input is strong enough,
then the postsynaptic neurons will be inhibited together
duringacertaintimewindowand,astheGABAARinhibitory
eﬀect decays, will escape from inhibition to resume ﬁring
nearly in synchrony (Figure 2). Such postinhibition syn-
chronous spiking of pyramidal cells can be elicited by
single-GABA neurons [28] and readily generates synchrony
throughout large numbers of neurons in computational net-
workmodels[7,67].Therefore,post-inhibitionsynchronous
spiking is a strong candidate mechanism for production of
neural synchrony. Alternative synchronization mechanisms,
which are not reviewed here, involve gap junctions connect-
ing pyramidal cell axons [8] or noisy but correlated inputs
[69].
Importantly, neuronal synchrony is commonly observed
during episodes of rhythmic/oscillatory network activity,
especially in association with cognitive tasks [70, 71].
Therefore, the circuit mechanisms of synchronized
oscillations via GABAAR-mediated inhibition must involve
rhythmic interneuron ﬁring and trains of IPSCs in their
postsynaptic target cells. As multiple subclasses of GABA
neuronsexist[72],acrucialissueiswhetherspeciﬁcsubtypes
are involved in the mechanisms of synchronized oscillations.
Synchronized oscillations occur at diﬀerent frequency bands
[70], including theta (∼4–10Hz), beta (∼15–30Hz), and
gamma (∼30–80Hz). Whether oscillations of all frequency
bands depend on GABAAR-mediated inhibition and, if
so, on particular GABA neuron subtypes is still a matter
of investigation [73]. Here we focus on models for the
mechanisms of gamma oscillations, which are commonly
induced during cognitive tasks and seem to be impaired in
the cortex of patients with schizophrenia.
Synchronization by the GABAAR-mediated mechanism
described in Figure 2 requires suﬃciently strong GABA
synapses activating a relatively large GABAA conductance
via inhibitory inputs localized near the site of action
potential initiation. In pyramidal cells, action potentials
are commonly triggered near the axon initial segment
(AIS), the axonal compartment that is closest to the soma
[74]. Therefore, inhibitory inputs onto the perisomatic
membrane compartment (soma, proximal dendrites,
and AIS) produce stronger inhibition than inputs onto
distal dendrites [75, 76], suggesting that perisomatic-
targeting GABA neurons may be crucially involved in
production of synchronized oscillations. Three main
subtypes of perisomatic-targeting GABA neurons exist in
neocortex and hippocampus, namely, the parvalbumin-
positive and the cholecystokinin-positive basket cells
(PVBCs and CCKBCs) and the PV-positive chandelier cells
(PVChCs). Both PVBCs and CCKBCs innervate pyramidal
GABA
neuron
Figure 2 :Am o d e lf o rG A B A AR-mediated synchronization mech-
anisms. The left panel shows a group of pyramidal cells that
are common postsynaptic targets of an inhibitory GABA neuron.
Perisomatic-targeting GABA neurons such as that in the scheme
producestrongerinhibitionthanGABAneuronsubtypesthattarget
the dendrites. The right panel shows, above (black trace), the mem-
brane potential of the GABA neuron which remains at rest before
and after ﬁring a sequence of four action potentials. The red traces
below show the membrane potential simultaneously recorded from
the postsynaptic pyramidal neurons, which are ﬁring in response to
a continuous excitatory input. Note that, before the GABA neuron
starts ﬁring, the pyramidal cells ﬁre in an asynchronous manner.
Shortly after the ﬁrst GABA neuron spike, an inhibitory postsynap-
tic potential (IPSP) is produced (ﬁrst black arrow) which simulta-
neously inhibits the ﬁring of all pyramidal neurons. After the IPSP-
mediated inhibition decays, the pyramidal neurons ﬁre in nearly
synchrony. Note that a similar postinhibition synchronization is
observed with each of the IPSPs evoked by the interneuron spikes
(each IPSP is denoted by a black arrow). Once the GABA neuron
stops ﬁring, pyramidal cell activity rapidly becomes asynchronous.
Also note that a single action potential in a GABA neuron would
synchronize the pyramidal cells only once, whereas production of a
synchronizedoscillationrequiresrhythmicGABAneuronﬁring.An
oscillation episode composed of four cycles is shown in the ﬁgure.
The production of synchronized oscillations via this mechanism
may be impaired by various alterations of GABAAR-mediated
synaptic inhibition in schizophrenia (see Figure 1 and main text).
cells at the soma and proximal dendrites (Figure 3),
whereasPVChCs synapseexclusivelyontotheAIS(Figure 3).
Because a synaptic GABAAR conductance has stronger
inhibitory eﬀect the closest it is localized to the site of spike
initiation [50], PVChC inputs onto the AIS are predicted to
have the strongest inhibitory power.
Surprisingly, some recent studies suggested that synaptic
input from PVChCs is actually excitatory, since stimula-
tion of PVChCs frequently initiates spikes in postsynaptic
pyramidal cells via GABAARa c t i v a t i o n[ 40]. In addition,
electron microscopy studies support the idea that PVChC
inputs are excitatory, as they show very low levels of KCC2
in the AIS compared to the soma or dendrites [40, 77].
Since KCC2 extrudes chloride, lower AIS levels of KCC2
should produce a more positive EGABAA, resulting in a depo-
larizing GABAARc u r r e n t( Figure 3)[ 43]. In fact, in paired
recordings using experimental conditions that preserve the
physiological intracellular chloride concentration, PVChC
inputs depolarize the postsynaptic pyramidal neurons [40,
78], whereas in identical experimental conditions PVBC
inputs are hyperpolarizing [40, 78], consistent with higher
levels of KCC2 transporters in the somatic membrane [40,
77]. Experiments with uncaging of GABA onto GABAARs in6 Neural Plasticity
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Figure 3: Diversity of perisomatic-targeting GABA neuron-mediated inhibition in cortical circuits may be due to diﬀerences in the reversal
potential for the GABAA-mediated current. (a) The scheme illustrates targeting by basket cells (either parvalbumin- or cholechystokinin-
positive), which contact the soma and the proximal/perisomatic dendritic compartments, and by chandelier or axoaxonic neurons, which
contact the axon initial segment. (b) The schemes illustrate diﬀerences in the postsynaptic eﬀect of a GABAAR conductance according to the
value of the reversal potential for the GABAA current (EGABAA) relative to the resting membrane potential (Vmr) and the threshold potential
to ﬁre spikes (Vth). In (B1) to (B3), the time course of the GABAAR-mediated conductance, chosen to be identical in all panels, is shown by
theblacktracesandtheIPSPsareshownbytheblue/redtraces.NotethattheIPSPtimecourseisalwaysslowerthantheGABAA conductance,
although in the scheme the diﬀerence in time course is somewhat exaggerated for illustration purposes and does not match the actual time
scales. (B1) Illustration of cases in which EGABAA is negative relative to Vmr (Vth >V mr >E GABAA), and the GABAA conductance generates a
hyperpolarizing IPSP (all blue IPSP trace). As the IPSP outlasts the GABAA conductance, the duration of the inhibitory eﬀect of the synaptic
input (shown by the shaded blue rectangle) is extended by the membrane hyperpolarization that remains after the GABAA conductance
decays. (B2) Illustration of cases in which the IPSP is depolarizing because EGABAA is positive relative to Vmr (Vth >E GABAA >V mr). Just as
the hyperpolarizing IPSP, the depolarizing IPSP outlasts the GABAA conductance; however, in this case EGABAA is below Vth, and therefore
the depolarizing IPSP could have a dual inhibitory/excitatory eﬀect (blue/red IPSP trace), initially producing shunting inhibition which
lasts approximately the same time as the GABAA conductance (shaded blue/red rectangle), followed by an enhanced excitability of the
postsynaptic neuron due to the remaining phase of the depolarizing IPSP. (B3) Illustration of cases in which EGABAA is positive relative
to Vth (EGABAA >V th >V mr). In this case, the depolarizing IPSP has a purely excitatory eﬀect (shaded red rectangle). Basket cells are
thought to produce hyperpolarizing GABAAR-mediated inhibition of pyramidal cells such as that illustrated in (B1). In contrast, the eﬀect
of chandelier neuron inputs is currently debatable, some studies suggesting an excitatory as that in (B3), other studies suggesting a purely
inhibitory eﬀect. Here, we suggest that depolarizing chandelier cell inputs may have a dual inhibitory/excitatory eﬀect, illustrated in (B2),
which could synchronize postsynaptic cells as described in Figure 2, although the depolarizing nature of the IPSP may accelerate the timing
of synchronous ﬁring after the postsynaptic cells escape from inhibition.
speciﬁc membrane compartments similarly showed a more
depolarized EGABAA at the AIS compared with the soma and
dendrites [79].
An excitatory depolarizing GABAAR-mediated input
by PVChCs is inconsistent with their participation in
inhibition-based synchronization. However, although
EGABAA at the AIS is 10–20mV depolarized before Vmr,i t
may be negative relative to Vth [40, 78, 79]. As highlighted
above, when Vth >E GABAA >V mr, the GABAA conductance
hasadualinhibitory/excitatoryeﬀect(Figure 3),whichinthe
case of PVChC inputs may be ampliﬁed by their proximity to
the spike initiation site. Such inhibitory/excitatory eﬀectmay
contribute to synchronization of postsynaptic cell activity
at gamma band frequency [7, 80]. Speciﬁcally, since the
postsynaptic potential outlasts the duration of the GABAAR
conductance(Figure 3), once the conductanceis deactivated,
the depolarizing postsynaptic potential accelerates the post-
inhibition synchronous spiking, facilitating synchronization
at gamma frequency. Such a mechanism operates at
GABAAR-mediated synapses onto GABA neurons [7, 80]
and could also apply at PVChC inputs onto pyramidal
neurons.
The depolarizing eﬀect of PVChCs described in neo-
cortex [40, 78] contrasts with pioneer paired record-
ing experiments showing that either PVBC or PVChC
inputs hyperpolarize hippocampal pyramidal neurons [26].Neural Plasticity 7
A hyperpolarizing eﬀect of hippocampal PVBCs and
PVChCs was also suggested recently by experiments using
conditions that preserve the intracellular chloride concen-
trations [81], but that are diﬀerent from the intracellu-
lar chloride-preserving conditions employed in studies of
neocortical PVChC inputs [40, 78]. Interestingly, the AIS
membrane has low levels of KCC2 in neocortical [40]
and hippocampal [77] pyramidal cells. The discrepan-
cies between ﬁndings for hippocampal versus neocortical
PVChCs highlight the need for further research to clarify the
enigmatic role of this class of GABA neurons [82]. Whether
excitatory or inhibitory, the unique properties of PVChC
inputs suggest that the reported alterations of these cells
must signiﬁcantly contribute to cortical circuit dysfunction
in schizophrenia [83].
In contrast to PVChCs, both PVBC and CCKBC inputs
are hyperpolarizing (Vmr >E GABAA), although EGABAA is
slightly, but signiﬁcantly, diﬀerent for PVBC versus CCKBC
inputs [84]. Such diﬀerences in EGABAA were attributed to
the activity of the voltage- and chloride-dependent chloride
channel ClC-2, which helps maintaining a low internal
chloride concentration (thus a hyperpolarized EGABAA)a t
inputs from PVBCs but not from CCKBCs [84]. The ClC-2-
dependent regulation of internal chloride at PVBC inputs is
dependent on the extent of GABAARa c t i v a t i o n[ 84]. These
ﬁndings highlight a degree of functional diversity between
BC subtypes, showing that PVBC inputs, but not CCKBC
inputs, possess a mechanism to prevent internal chloride
accumulation during high-frequency neuronal activity such
as that observed in GABA neurons participating in gamma
oscillations.
Functional diversity between PVBCs, PVChCs and CCK-
BCs is also suggested by recent data demonstrating that
the relative levels of GAD65 and GAD67 proteins in nerve
terminals of these cells vary signiﬁcantly in a cell-type-
speciﬁc manner [85]. Using immunocytochemical label-
ing combined with a quantitative ﬂuorescence microscopy
methodology [86], the colocalization of GAD65 and GAD67
proteins in the same terminals was assessed for PVBCs,
PVChCs and CCKBCs (Figure 4). The latter cells were
identiﬁed using an antibody that detects the cannabinoid
1 receptors expressed by inhibitory terminals. Importantly,
in the prefrontal cortex nearly all cannabinoid 1 receptor-
expressing cells detected using this antibody are immunore-
active for CCK [87]. This assessment showed that the ratio
ofGAD67/GAD65expressionvariedsigniﬁcantlyacrosseach
type of terminal, with very high (15.42) and very low
(0.18) ratios observed in terminals of PVChCs and CCKBCs,
respectively, and a ratio of 1.49 for PVBC terminals [85].
These data reinforce the idea that synaptic connections from
diﬀerent perisomatic-targeting GABA neuron subtypes are
functionally diverse. The impact of diﬀerent GAD67/GAD65
ratio on the properties of the GABA synapses studied
remains enigmatic because the diﬀerential functional roles
of GAD67 and GAD65 are still poorly understood. In mice,
GAD67 deﬁciency produces major alterations, as GAD67−/−
animals are born with cleft palate (which is lethal) and
with ∼90% reduction of bulk GABA concentration in brain
tissue [88, 89]. In contrast, GAD65−/− mice survive into
adulthood, displaying ∼20% reduction in total brain GABA
concentration [90] together with increased susceptibility
to seizures [90, 91], increased anxiety [92], and altered
fear conditioning [93]. In synapses of GAD65−/− mice,
GABAAR-mediated synaptic transmission appears normal
during low-frequency stimulation but is strongly impaired
at stimulation frequency of 30Hz or higher [94, 95]. In mice
with cerebellum-speciﬁc GAD67 deﬁciency [96], GABAAR-
mediated transmission is markedly weaker even at low
stimulus frequency [96], suggesting a crucial role of GAD67
in baseline synaptic transmission. Whether the eﬀects of
GAD67deﬁciencyoncerebellarsynapsesareobservedincor-
tical synapses as well remains to be determined. Importantly,
GAD67 deﬁciency markedly impairs the maturation of corti-
cal GABAergic synaptic connections [97]. Therefore, testing
the role of GAD67 in synaptic transmission independent
of its role in synapse development requires a paradigm in
which GAD67 is decreased once GABA synapse maturation
has been completed. In addition, GAD65 and GAD67 both
comprise ∼50% of total GAD protein in mouse cortex, while
GAD65 comprises ∼70% in the rat cortex [98]. The GAD65
and GAD67 proportions of the total GAD protein in human
cortex is unknown; however, the diﬀerences between mouse
and rat strongly stress the need to study GAD function in
molecularlyrelevantsystemswhentryingtounderstandtheir
roles in human disease.
GABAAR-mediated inputs involved in gamma band
synchronization must inhibit their postsynaptic neurons for
a time compatible with the gamma oscillation period. For
instance, long-lasting postsynaptic currents such as those
activated by GABAB receptors (which may last hundreds
of milliseconds) are inconsistent with gamma synchrony,
as postsynaptic neuron inhibition would be longer than
the typical gamma cycle period. Whereas all GABAAR
subtypes produce faster currents than GABAB receptors, the
GABAAcurrent duration depends on the subunit composi-
tion[43, 99]. As mentioned, recombinantα1-GABAARs pro-
duce currents with the fastest decay [100]. Therefore, PVBCs
may produce IPSCs with faster decay, as α1-GABAARs pre-
dominate at inputs from PVBCs [33, 41, 101, 102]w h e r e a s
α2-GABAARs predominate at both PVChC and CCKBC
inputs [41, 101–103]. Interestingly, PVBCs, CCKBCs, and
PVChCs elicit in pyramidal cells uIPSCs with nearly iden-
tical kinetics [39, 104–107]. Therefore, in addition to
the GABAAR subunit composition, the IPSC kinetics are
determined by additional factors that may not aﬀect recom-
binant GABAARs. Such factors include GABAAR subunit
phosphorylation and other posttranslational modiﬁcations
[108, 109], and the time course of the GABA concentration
transient to which GABAARs are exposed [41].
Although PVBCs and CCKBCs produce IPSCs with sim-
ilar duration during individual GABA release events, CCK-
BCs distinctively produce multiple asynchronous release
events after single-action potentials [104]. Multiple GABA
release events may prolong the postsynaptic inhibitory
eﬀect of each CCKBC spike [104]. In contrast, PVBC
terminals produce a single synchronous GABA release event
per presynaptic action potential [104, 110]. Asynchronous
releasefromCCKBCterminalshasbeenobservedinmultiple8 Neural Plasticity
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Figure 4: Relative levels of GAD65 and GAD67 in PVCh, PVBC, and CCKBC terminals. Cryostat sections of monkey PFC tissue (40μm
thick) were quadruple labeled for GAD65, GAD67, PV, and cannabinoid receptor 1 (CB1r). Among inhibitory synaptic boutons, CB1r is
exclusively expressed in those CCK-positive neurons and is completely absent in terminals of PV-positive neurons. Presynaptic CB1rs are
also present in excitatory synapses; however, the antibody used in the studies illustrated in this ﬁgure exclusively reveal CB1r expression in
inhibitory boutons (see main text for details). Therefore, CB1r expression is a marker of CCK cell terminals. Single channel (a)-(b) and (d)-
(e) and merged (c) and (f) projection images of deconvolved image stacks (2 z-planes 0.25μm apart). Since four labels cannot be displayed
together in a single image, they have been separated into two RGB images that contain GAD67 (red), GAD65 (green), and PV (blue (c)) or
CB1r (blue (f)). Arrows: PV cartridge; solid arrowheads: CB1r+/GAD65+ and GAD67− terminals; open arrowheads: GAD65+/GAD67+/PV+
terminals. Bar=10μm.
studies [104, 107, 111–115] suggesting that it is a fundamen-
tal property that prolongs the inhibitory eﬀect of CCKBCs
on postsynaptic neurons possibly linking their activity with
synchronization at frequency bands lower than gamma.
Thedatareviewedabovesuggestthat,relativetoCCKBCs
and PVChCs, PVBCs have unique properties consistent with
a crucial role in the mechanisms of gamma band synchrony.
However, such data do not directly assess involvement of any
of these GABA neuron subtypes in the gamma oscillation
mechanisms. Interestingly, some electrophysiological studies
more directly indicate that among perisomatic-targeting
GABAneuronsubtypes,PVBCsaremostlikelytobeinvolved
in the production of gamma oscillations. For instance,
whereas both BCs and ChCs are active during gamma oscil-
lations in vivo [116–118] and in vitro [119–124], the ﬁring
of CCKBCs and PVChCs is more weakly coupled with the
gamma oscillation cycle than PVBC ﬁring [124], although
CCKBC and PVChC ﬁring is strongly coupled with theta
oscillations [125–127]. Furthermore, gamma oscillations are
signiﬁcantly reduced or abolished by suppressing PV cell
activity with optogenetic methods that do not directly aﬀect
CCKBCs [128] or by stimulation of presynaptic opioid
receptors that suppress GABA release from PVBCs but
not from CCKBCs or ChCs [124]. Therefore, perisomatic
GABAAR-mediated currents from PVBCs appear to be the
main source of GABAAR-mediated synchronization in the
gamma frequency band.
Essential for modeling the circuit mechanisms of gamma
synchronization is to understand how PVBCs are normally
recruited to ﬁre rhythmically at gamma frequency. Recruit-
ment of PVBC ﬁring depends on activation of not only
excitatory but also inhibitory synaptic inputs onto them
since PVBCs target other GABA neurons, including nearby
PVBCs [129, 130], and are also inhibited by inputs fromNeural Plasticity 9
diﬀerent classes of GABA neurons, including the CCK-
BCs [112]. Gamma oscillations are successfully generated
in computational model networks that rely on reciprocal
inhibition between GABA neurons and are thus called
ING, for Interneuron Network Gamma [131–133]. In ING
models, GABA neurons are recruited by a strong tonic
excitation that drives them to ﬁre at a frequency above
gamma, and the reciprocal inhibition synchronizes GABA
neuron ﬁring at a frequency inversely related to the IPSC
duration, falling within gamma range for durations typical
of α1-GABAAR-mediated IPSCs [132, 133]. Whereas gamma
rhythms possibly induced by ING-like mechanisms have
been observed experimentally [134], the actual source of
the strong tonic excitation onto GABA neurons required by
ING models is unclear. Metabotropic glutamate receptors
[67, 134] or kainate receptors [135] could provide such
a tonic drive, although this possibility is supported, only
indirectly, by ﬁndings obtained with AMPA- and NMDA-
mediated synaptic transmission blocked. A recent study
employing genetically engineered mice with a deletion of
GABAAR expression in PVBCs [136] directly tested whether
inhibition onto PVBCs is necessary to generate gamma
oscillations, as predicted by the ING models. In such
mice,GABAAR-mediatedIPSCswereabolishedexclusivelyin
PVBCs [136] and theta oscillations and their coupling with
gamma oscillations were severely disrupted [136]. However,
in such mice hippocampal gamma oscillations in vivo were
intact as compared with wild-type mice [136]. These data
argue against the ING model for gamma band synchrony
and suggest that inhibition onto PVBCs, potentially from
CCKBCs [112], is crucial for coupling theta and gamma
oscillations. Such theta-gamma coupling is thought to be
important for cognitive function [137].
As the role of ING mechanisms in gamma oscillation
production continues to be tested, some studies favor
an alternative model, known as Pyramidal Interneuron
Network Gamma (PING), which depends on recurrent
excitatory-inhibitory synaptic interactions. In PING, PVBCs
are recruited by phasic glutamate-mediated inputs from the
pyramidal cells, and the PVBCs provide strong feedback
inhibition that synchronizes pyramidal cell ﬁring [67, 121,
138]. The PING model predicts that during the gamma
oscillationcyclePVBCsﬁreafterthepyramidalneurons,with
timing consistent with monosynaptic recruitment by pyra-
midal cells [138]. The spike timing of pyramidal cells and
putative BCs during gamma oscillations in awake behaving
animals is actually consistent with the PING model, as BCs
ﬁre 2-3ms later than pyramidal neurons [139, 140]. Similar
ﬁndings were obtained for pyramidal and PVBC spikes
during gamma oscillations in hippocampal and neocortical
brain slices [119, 120, 122, 123, 141]. PING models also
predict the presence of trains of gamma frequency IPSCs in
pyramidal neurons and trains of gamma frequency EPSCs in
PVBCs [67]. Evidence consistent with IPSC trains in pyra-
midal cells was obtained for gamma oscillations in vivo [117,
142] and in vitro [119–123, 141, 142]. In addition, during
gamma oscillations in vitro, PVBCs display rhythmic EPSCs
highly synchronized with the gamma rhythm [120–122].
Interestingly,optogeneticsexperimentsshowthatdrivingPV
neurons by nonrhythmic excitatory inputs is suﬃcient to
generate gamma synchrony via feedback inhibition [128], a
ﬁnding also consistent with the PING model of gamma.
PING mechanisms rely on recruitment of PVBCs by
phasic excitatory input [138]; therefore, the properties of
glutamate synapses onto PV neurons are extremely relevant
for models of gamma oscillations. Interestingly, schizophre-
nia has been hypothesized to be associated with a deﬁcit
of glutamate transmission [143], more speciﬁcally with
hypofunction of NMDA receptors, particularly in GABA
neurons [143]. Moreover, some studies have suggested that
NMDA hypofunction could especially aﬀect PV cells [144–
146].Therefore,animportantquestionisthefollowing:what
arethesubtypesofglutamatereceptorsthatmediatesynaptic
activation of PV GABA neurons? The answer to this question
is relevant in the context of alterations of gamma synchrony
in schizophrenia, because if NMDA receptors are important
to recruit PV neurons in a PING mechanism of gamma,
then NMDA hypofunction could be linked to deﬁcits of
gammasynchronyinschizophrenia.Datafromrecentstudies
showed that systemic administration of NMDA receptor
antagonists increase the ﬁring rate of putative pyramidal
neurons and decrease the ﬁring of putative inhibitory cells
in the PFC in vivo [147], suggesting that NMDA receptors
may be crucial to recruit inhibition. An important question
not directly addressed by such studies [147] is whether the
inhibitory neurons dependent on NMDA receptors belong
to the PV-positive class of GABA neurons. Whereas several
studies demonstrated that synaptic excitation of PV neurons
is relatively NMDA receptor independent, until recently
no studies directly compared the importance of NMDA
receptors in synaptically evoked recruitment of PVBCs
versus pyramidal neurons in neocortical circuits. Recent data
from recordings in mouse PFC show that, compared with
pyramidal cells, glutamate synapses onto PVBCs have EPSCs
with faster decay and weaker NMDA receptor contribution
[148],supportingtheideathattherapidactivationofPVBCs
[149] is largely dependent on fast AMPA receptor-mediated
excitation. Moreover, in a computational model producing
gamma oscillations via PING mechanisms, fast AMPA-
mediated excitation of PVBCs was critical for gamma band
synchronization because the slower decay time course of
NMDA-mediated EPSCs disrupted gamma band synchrony
[148]. Some studies indeed showed that gamma oscillations
are not aﬀected or are enhanced by NMDA receptor
antagonists, whereas AMPA receptor antagonism completely
abolished them [150–153]. Similarly, in mice with AMPA
receptor deletion genetically engineered to occur exclusively
in PV-positive neurons, gamma oscillations are strongly
reduced [154]; however, NMDA receptor deletion selectively
in PV-positive cells does not decrease and in fact increases
gamma oscillation power [155]. The results of recent studies
therefore suggest that, in mature cortical circuits, NMDA
receptors only play a minor role in synaptically evoked
excitation of PV-positive neurons and therefore on gamma
oscillations produced via PING mechanisms. If indeed PV
neuron excitation is normally weakly dependent on NMDA
receptors, then such data suggest that excitatory synapses
onto PV cells are an unlikely target of NMDA receptor10 Neural Plasticity
hypofunction mechanisms in schizophrenia. Importantly,
although in most cases gamma synchrony is unaﬀected by
NMDA receptor blockade, the eﬀects of NMDA receptor
antagonists on gamma oscillations may vary with cortical
region or layer, in some cases ketamine producing a decrease,
in others producing an increase in gamma power [152, 156].
In addition, some data show that whereas mature PVBCs
display a relatively small NMDA receptor mediated com-
ponent in synaptic responses [148, 157, 158], such NMDA
component is substantially more prominent in immature
PVBCs [157, 158]. Such ﬁndings suggest the interesting
possibility that alterations of NMDA receptor-signaling
during early brain development could alter PVBC function
in ways that persist into adulthood, thus changing the role of
PVBCs in mature local circuits. Interestingly, a recent study
showed that a genetically engineered deletion of NMDA
receptors from PV-positive cells does not have signiﬁcant
eﬀects if the deletion is produced in the brain of adult mice
[159]. However, a similar deletion produced during early
brain development caused behavioral alterations in adult
mice, some of which resemble behavioral dysfunction in
patients with schizophrenia [159].
5. PostnatalDevelopment of GABA-Mediated
Synaptic Inhibition
Schizophrenia is hypothesized to be a neurodevelopmental
disorder based on data linking the disease with adverse
events during pre- and perinatal periods and the presence
of cognitive and behavioral deﬁcits in childhood many years
prior to the onset of psychosis during late adolescence
and early adulthood [160]. Adolescence, the developmental
transition from parent-dependent childhood to independent
adulthood, is associated with signiﬁcant changes in behav-
ior and with marked improvements in cognitive control
[161]. Moreover, gamma band synchrony emerges during
childhood and continues to mature until early adulthood
[162,163].ThepostnataldevelopmentaltrajectoryofGABA-
synaptic function may therefore suggest critical periods
of vulnerability during which the mechanisms producing
neuralsynchronycouldbecomedysfunctionalinschizophre-
nia. In what follows we review developmental studies of
the functional properties of PVBCs and their synaptic
connections in rodents and of GABA-related gene products
studied in the human and nonhuman primate brain.
MaturePVneuronshaveauniquefast-spiking(FS)ﬁring
pattern (Figure 5), which includes very narrow action poten-
tials and high frequency ﬁring without the spike-frequency
adaptation typically observed in pyramidal cells and other
GABA neuron subtypes [72]. Although the nonadapting
properties of FS cells are revealed with artiﬁcial stimuli
(rectangular currents steps lasting several hundred ms), they
correlate strongly with the particular ability of FS cells to
respond to oscillatory inputs at gamma frequency (Figure 5),
which is likely due to the gamma frequency resonance of the
FS cell membrane [164]. Immature FS neurons, in contrast,
have signiﬁcantly slower action potentials and stronger
spike-frequency adaptation, fail to respond eﬃciently to
gamma frequency oscillatory inputs, and show much slower
conduction velocity of action potentials along their axon
[33,165–167].Inrodenthippocampus,aswellasinauditory,
somatosensory, and prefrontal cortices, maturation of FS
neuron electrical properties is complete by postnatal day 25
(P25) after which FS neurons display adult-like electrical
properties [33, 157, 165–167].
Functional properties of the inhibitory connections onto
excitatory neurons also diﬀer markedly between developing
and mature PVBCs: unitary IPSCs (uIPSCs), from immature
PVBCs, are weaker and have slower decay time than uIPSCs
produced by mature PVBCs [33, 168]. Such acceleration of
uIPSC decay is explained by an increase in the contribution
of α1-GABAARs with maturation [33]. A GABAAR subunit
switchmayalsocontributetothedevelopmentalacceleration
of the uIPSP decay [167] although developmental changes
in the pyramidal cell membrane time constant contribute
as well [167]. Mature FSBCs produce highly synchronous
GABA release, in contrast to asynchronous release from
mature CCKBCs [33, 104, 110]. However, GABA release is
lesssynchronousandlessreliableinsynapsesfromimmature
FSBCs [33]. Postnatal maturation of the FSBC connections
takes place relatively rapidly, as uIPSCs acquire mature
properties by P28 [33, 167].
Inhibition onto FS cells also undergoes signiﬁcant
developmental changes. For example, uIPSCs at FSBC-to-
FSBC connections mature within 3-4 weeks postnatally [33],
whereas miniature IPSCs (mIPSCs, which represent GABA
release at single synapses) recorded from FSBCs acquire
adult-like properties by P25 [165]. Unitary EPSPs (uEPSPs)
at immature pyramidal cell-to-FSBC connections have slow
decay time, which accelerates markedly during develop-
ment, reaching adult-like values by ∼P22 [167]. Similarly,
miniature EPSCs (mEPSCs) recorded from immature FSBCs
are slow and show a developmental acceleration of their
decay to reach very fast mEPSC decay values in mature
FS cells [148, 157, 158, 165]. Fast-decaying EPSCs and
EPSPs in mature FSBCs are largely mediated by AMPA
receptors [148, 157, 158, 167, 169], suggesting that the rapid
EPSC decay in FSBCs is due, at least in part, to a weak
contribution from the slow-decaying NMDA currents [148,
157].Actually,thedevelopmentalaccelerationofEPSCdecay
is accompanied by a marked decrease in the contribution
of NMDA currents which is still ongoing at ∼P40 to ∼
P96 [157], which in rodents corresponds to the transition
from adolescence to adulthood [170]. In contrast to PFC,
in hippocampus, auditory, and somatosensory cortices,
NMDA receptor contribution in FSBCs decreases prior to
adolescence [167, 169, 171, 172].
Althoughthemechanismscontrollingpostnataldevelop-
ment of PVBC ﬁring properties and their synaptic inputs
and outputs are important candidates as the substrate of
alterations in schizophrenia, they are still poorly understood.
Neuregulin-1 is a trophic factor crucial for brain devel-
opment that is encoded by a schizophrenia susceptibility
gene and is highly expressed during late developmental
periods and in adulthood [173, 174]. Among various
neuregulin-1 receptors, the ErbB4 receptor, whose gene also
confersschizophreniasusceptibility[173,174],isenrichedin
GABA neurons, particularly in PV-positive cells [175, 176]Neural Plasticity 11
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Figure 5: Intrinsic electrical properties of parvalbumin-positive GABA neurons. (a) Single action potentials in fast-spiking PV-positive
neurons (FS) have signiﬁcantly faster duration than pyramidal cell (PC) spikes or spikes in many other GABA neuron subtypes (not shown).
(b) In response to sustained depolarizing current injection (500ms rectangular current pulses shown below the traces), PCs produce high-
frequency ﬁring with signiﬁcant spike-frequency adaptation as revealed by comparing the ﬁrst and last interspike intervals (ISI). In contrast,
adaptation of FS cell ﬁring is much less signiﬁcant or absent. (c) In response to gamma wave stimulation (sinusoidal current pulses shown
below the traces), PCs show low capacity to respond with ﬁring during each cycle of the gamma wave stimulus. (d) In response to gamma
wave stimulation, FS cells show increased ﬁring capacity, initiating spikes in the majority of gamma wave cycles. This property of the FS
neuron membrane may contribute to the activation of FS neurons during gamma oscillations in vivo and is likely due to the resonance or
frequency-preference properties (see text) that distinguish FS cells from PCs and also from other GABA neuron subtypes.
where it facilitates GABA release [176], possibly mediating
neuregulin-1 enhancement of gamma oscillations [177].
Neuregulin-1 signaling appears to regulate early develop-
ment of GABA synapses [178]a n d ,v i aE r b B 4r e c e p t o r s ,m a y
control development of PV neuron synapses [179]. Inter-
estingly, ErbB4-mediated neuregulin-1 eﬀects are crucial for
development of excitatory synapses onto PVBCs [179, 180].
In parallel to the maturation of their ﬁring pattern and
synaptic connections, PVBCs undergo signiﬁcant develop-
mental morphological changes. For instance, the total length
of the dendritic and axonal trees of PVBCs increases signif-
icantly from P6 to P25 [33], the number of axonal branch
pointsincreasingﬁvetimesduringthisdevelopmentalperiod
[33]. The number of postsynaptic neurons innervated by
individual PVBCs also increases markedly with postnatal
development [97], resulting in a higher functional connec-
tivity between mature PVBCs and excitatory neurons [33].
A crucial factor regulating development of innervation
patterns by PVBCs is GAD67-mediated GABA synthesis
[97]. For instance, GAD67 knockdown in single PVBCs
dramatically decreases formation of axon branches and
synapses, as well as the number of postsynaptic neurons
innervated by each PVBC [97]. Such eﬀects of GAD67
knock-down are observed in organotypic cell cultures and
in the primary visual cortex in vivo with GAD67 knock-
down induced at P13 and the patterns of innervation
examined at P20 or P32 [97]. The role of GAD67-mediated
GABA synthesis in formation and/or stability of PVBC
synapses may involve neuroligin-neurexin interactions and
modulation of GABA receptor traﬃcking [181].
Because detailed molecular and biophysical analysis of
developmental changes in GABA neuron and GABA synapse
function is feasible only using animal models, especially
rodents, an important question is how developmental time12 Neural Plasticity
scales translate from animal to human brain [182]. Proper
translation would require understanding if similar devel-
opmental stages are found in rodent and human brains,
whether such developmental stages involve similar processes
and underlying mechanisms, and whether developmental
periods cover similar fractions of the total lifespan. Some
developmental changes, for instance, excitatory synapse
pruning, have similar proportional duration, with only
the extent of synaptic pruning diﬀering across mammalian
species [183]. Also, functional maturation of glutamate
synapses onto pyramidal cells occurs prior to adolescence in
nonhuman primates [184], and in rodents [185–191].
Whereas some unique studies have assessed functional
properties of PVBCs and PVChCs in the cortex of adult
humans [40, 192, 193] and nonhuman primates [39, 184,
194–197], we lack information on the developmental tra-
jectory of synaptic inhibition from primate PV neurons.
Interestingly, functional properties of yet unidentiﬁed GABA
synapses onto primate pyramidal neurons change during
development through adolescence in a manner consistent
with changes in the expression of gene products involved in
GABA-mediated transmission [198]. Speciﬁcally, the decay
time of GABAAR-mediated synaptic potentials accelerates
during adolescence in parallel to changes in the protein
and/or mRNA levels for α1a n dα2 GABAAR subunits that
would predict such acceleration [198].
The synaptic connections from PVChCs onto the pyra-
midal cell AIS form vertical arrays of multiple synaptic
boutons that are usually easy to distinguish and typically
called cartridges. Developmental properties of inputs from
PVChCs onto the AIS can be studied using immunocyto-
chemistry to detect biochemical markers that are concen-
trated at the cartridges in the AIS. In monkey PFC, the den-
sity of chandelier neuron axon cartridges immunoreactive
for either PV or GAT1 changes markedly during postnatal
development [199]. Although the precise time course diﬀers
forthetwomarkers,thedensityoflabeledcartridgesislowin
the newborn, increases to reach a peak prior to the onset of
puberty, and then declines markedly to adult levels. Because
cartridges are readily visualized with the Golgi technique
over this same time period [200], the changes in PV- and
GAT1-immunoreactive cartridges may reﬂect developmental
shifts in the concentration of these proteins, rather than
in the number of axon terminals, but this remains to be
experimentally assessed.
Substantial developmental changes also occur postsy-
naptically at the AIS. In the adult cortex, the majority of
α2-GABAARs are found in pyramidal cell AIS [201]. The
detectability of GABAAα2 subunits in AIS is very high in
the early postnatal period and then steadily declines through
adolescence into adulthood [199]. Immunoreactivity for
ankyrin-G, βIV spectrin, and gephyrin (a scaﬀolding pro-
tein that regulates the clustering of GABAARs containing
α2 subunits at AIS) [202–204] also exhibit substantial
changes during postnatal development [205]. The densities
of ankyrin-G and βIV spectrin immunoreactive AISs are
greatest at birth and then sharply decline to reach relatively
stable values by one year of age. In contrast, the relative
density of gephyrin-immunoreactive AIS did not appear to
change through the two postnatal years but then sharply
decline through adolescence and into adulthood.
The high density of AIS with detectable levels of ankyrin-
G immunoreactivity in the ﬁrst three postnatal months may
reﬂect the recruitment to this location of a portion of the
large number of GABA synapses that are formed in the
monkey DLPFC during this developmental epoch [206].
Binding to ankyrin-G is also essential for the localization of
many other membrane proteins to the AIS [207], including
the voltage-gated Na+ channels that are required for action
potential generation [208]. Thus, the high levels of ankyrin-
G immunoreactivity may also indicate an increased capacity
of pyramidal neurons for repetitive ﬁring that parallels
their increase in excitatory inputs during early postnatal
development [206, 209]. The parallel relative densities of
ankyrin-G-IR and βIV spectrin-SD-IR AIS likely reﬂect
that ankyrin-G is required for the recruitment of βIV
spectrin to AIS [210]. Although βIV spectrin is not essential
for the formation of the AIS, it does appear necessary
for maintenance of membrane structure and molecular
organization [211], and thus the stability [210], of the AIS.
Giventhegeneralroleofspectrinsinmaintaining membrane
integrity and elasticity [207], high levels of βIV spectrin
during early postnatal development might insure the sta-
bility of AIS structure while PFC thickness is increasing
[212].
Interestingly, in human PFC the levels of GAD67 mRNA
increase progressively during prenatal and postnatal devel-
opment through childhood until around the peripubertal
period, followed by a plateau or mild decline during aging
[213]. A similar pattern was reported for GAD67 mRNA
expression during mouse [213] and monkey [214]c o r t i c a l
development, suggesting a highly conserved developmental
trajectory of GAD67 expression across mammals. Studying
protein expression by immunoblotting, a recent study found
that GAD67 protein levels did not change across the
lifespan in human visual cortex [215]. In contrast, GAD65
showed a progressive 60% increase until teenage years and
young adulthood, followed by slight decline in older adults
[215]. Two other presynaptic proteins involved in GABA
transmission, the cannabinoid receptor 1 and vGAT, showed
higher levels in infants and young children, which declined
to adult-like levels in preteenage years [215] .T h el e v e l so f
PV mRNA increase markedly in postnatal human PFC, from
very low perinatal levels until adult-like levels are reached
by 2–5 years of age [216], an early developmental trajectory
which is similar to that reported for PV mRNA and protein
in rodent neocortex [217, 218].
Interestingly, a comparative analysis using immunolo-
calization of the chloride transporters NKCC1 and KCC2
revealed a very similar developmental trajectory in rat and
human cortex [219]. NKCC1 levels peaking during perinatal
development and decaying rapidly thereafter reach adult-like
levels during childhood; conversely, KCC2 is undetectable
perinatally and increases until reaching adult levels during
childhood [219]. Since the NKCC1/KCC2 activity ratio
determines whether GABAAR-mediated IPSCs depolarize or
hyperpolarizethepostsynapticmembrane,thesedatasuggest
that the very early developmental switch from excitatory toNeural Plasticity 13
inhibitory eﬀects at most GABA synapses [220] is highly
conserved between rodent and human neocortex.
Analysis of GABAAR subunit proteins during postna-
tal development in human visual cortex showed that α1
GABAARsubunitlevelsincreasefrom<1yearsuntilreaching
adultlevelsat13.5yearsofage,whereasα2GABAARsubunits
decreased signiﬁcantly with age to reach adult levels by ∼
10 years and α3 GABAAR subunit levels do not change
signiﬁcantlywithage[215].Consequently,theα1/α2subunit
protein ratio increased markedly with development attaining
adult-like ratios at 4.5 years of age [215]. Remarkably, very
similar developmental trajectories were found for the levels
of GABAAR subunit mRNAs in postmortem samples of
humanPFC[221].Forexample,α1GABAARsubunitmRNA
levels are very low perinatally and increase markedly until
toddler ages, thereafter remaining consistently high through
to adulthood [221]. In contrast, α2 subunit mRNA increased
during the ﬁrst postnatal months, decreasing subsequently
until reaching mature levels at teenage years or young
adulthood[221].ThemRNAsforα4andα5GABAA subunits
in human PFC showed a developmental pattern similar
to that of α2 mRNA, whereas α3 subunit mRNA did not
change signiﬁcantly with age [221]. Postnatal expression
of mRNA for γ and β GABAAR subunits similarly shows
signiﬁcantage-dependentchanges,withβ1subunitsshowing
a very early developmental decrease between neonate and
infant ages, remaining constant thereafter, and β2 increasing
somewhat later, between toddler and teenage years [222]. On
theotherhand,γ1andγ3subunitmRNAlevelsdecreasewith
age during childhood and teenage years, whereas γ2 subunit
mRNA levels decrease over the same period [222].
The developmental trajectories reviewed above suggest
that similar processes underlie developmental changes in
GABAAR-mediated synapses across various areas of human
and rodent cortex, although further studies are necessary to
properly compare developmental trajectories across species.
Am a j o rd i ﬀerence between species is that the maturation
of GABA-related markers in humans involves progressive
change over one to two decades, whereas in rodents GABA
synapse maturation appears to be complete within 3-4
postnatal weeks. Such diﬀerence suggests that the absolute
time window during which activity and experience may
inﬂuence GABA synapse development is markedly expanded
in primate versus rodent brains. The prolonged period that
may be necessary for the normal developmental tuning of
the more complex circuitry of the primate cortex probably
also prolongs the time window during which environmental
factors can produce subtle developmental alterations that
may contribute to the pathophysiology of schizophrenia.
6. EvidenceSuggestingAlterations of
GABAAR-MediatedSynapticTransmissionin
the Cortex of Schizophrenia Patients
ThehypothesisthatadeﬁcitinGABAAR-mediatedtransmis-
sion underlies cortical circuit dysfunction in schizophrenia
is supported by convergent lines of evidence from post-
mortem studies of the brain of subjects with schizophrenia
[6]. Furthermore, such hypothesis is strengthened by the
fact that one of the most reliably replicated ﬁndings in
schizophrenia research is the decrease in GAD67 mRNA (for
review, see [223]). Interestingly, equivalent measurements of
GAD65 levels thus far failed to reveal alterations, suggesting
that the role of GAD65 in GABA-mediated transmission
maybe intact in schizophrenia.
A remarkable recent study found that in schizophre-
nia several GABA-related transcripts, including those for
GAD67, PV, GAT1, somatostatin, and the GABAAR subunits
α1a n dδ, show decreased levels in dorsolateral PFC as well
as in the anterior cingulate, primary motor, and primary
visual cortices [224]. Such conserved regional pattern of
GABA alterations suggests that dysfunctional GABA neu-
rotransmission contributes to multiple clinical features of
schizophrenia including perceptual and motor deﬁcits that
could contribute to impaired cognitive function [11]. The
disruption of PV expression across cortical areas conﬁrms
thepreviousﬁndingsand,moreover,suggeststhatalterations
of PV-positive cells are central to the schizophrenia disease
process, although the consequences of such decrease in PV
are not completely understood. PV is a Ca2+ buﬀer that is
present in nerve terminals of PV-positive neurons (Figure 1).
Due to its slow kinetics of Ca2+ binding, PV is unable to bind
intracellularCa2+ beforeCa2+ inﬂuxactivatestheCa2+ sensor
that triggers GABA release, because in PV-positive terminals
Ca2+ inﬂux is tightly coupled with GABA release [110, 225].
Interestingly, GABA release by single stimuli does not diﬀer
between PV-deﬁcient and wild-type mice, but PV deﬁciency
facilitates repetitive GABA release [226–228]. In synapses
from PV-deﬁcient mice, the amplitude of intracellular Ca2+
transients in nerve terminals is not aﬀected, but their decay
is slowed, indicating that PV normally accelerates such decay
[227, 228]. Therefore, one possibility is that the decrease of
PV in schizophrenia, instead of contributing to deﬁcits, is
a compensatory response to enhance GABA release in the
face of decreased GABA synthesis. Alternatively, reduced PV
levels may produce synaptic dysfunction via loss of some
asynchronous release normally produced when Ca2+unbinds
from PV, well after the presynaptic action potential ended
[145]. A pathological loss of asynchronous GABA release
by decreased PV levels, however, requires the existence of
asynchronous release when PV is intact, a feature that is not
observed in cortical PV-positive cells [104, 110], although it
is found in PV-positive cerebellar interneurons [227].
Whereas schizophrenia may be associated with an
increased density of α2-GABAARs at the AIS synapses from
PVChCs [6], one study failed to detect signiﬁcant changes
in total tissue levels of α2-GABAARm R N A[ 221]. One
possibility is that changes in α2-GABAARs are synapse- or
layer-speciﬁc and perhaps found exclusively at AIS synapses
in superﬁcial cortical layers, as initially reported [229].
Consistent with this interpretation, laminar analysis of
mRNA levels for GABAAR subunits in the cortex of subjects
with schizophrenia revealed signiﬁcantly increased levels
of mRNA for α2 GABAAR subunits exclusively in layer 2
[230]. Moreover, the same study revealed lower levels of α1
GABAAR subunit mRNA in layers 3 and 4 [230], which is
consistentwithadecreaseintotaltissuelevelsof α1GABAAR14 Neural Plasticity
subunit mRNA observed using quantitative PCR [224].
Giventhatα1subunit-containingGABAARsconstituteabout
60% of the total GABAARs in adult brain [231], it is possible
that α1 subunit mRNA is signiﬁcantly more abundant than
that for α2 subunits, thus increasing the chance of detecting
changes of total tissue α1 mRNA levels in schizophrenia.
Importantly, a decrease in α1 subunits in schizophrenia is
consistent with weaker synaptic transmission from PVBCs,
since α1 subunit-containing GABAARs are predominant at
synapses from mature PVBCs [33, 41, 101, 102].
In addition to GABAAR levels, the strength of the
postsynaptic response to GABA depends on the driving force
for the GABAAR current which is determined by its reversal
potential EGABAA.A sEGABAA depends on chloride extrusion
by KCC2 and chloride uptake by NKCC1 [43], a recent study
examined mRNA expression for both chloride transporters
in the cortex of subjects with schizophrenia [232]. Interest-
ingly, KCC2 and NKCC1 transcript levels were not altered
in subjects with schizophrenia; however, transcripts for two
kinases (OXSR1 and WNK3) that strongly regulate KCC2
andNKCC1activityinoppositedirections,areoverexpressed
in schizophrenia [232]. If increased levels of OXSR1 and
WNK3 mRNA actually represent increased kinase activity,
thenthechloridegradientacrossthepostsynapticmembrane
may be decreased, resulting in an EGABAA signiﬁcantly more
depolarizedthannormal[232].SincenormallyEGABAA varies
with cell type and subcellular compartment, understanding
theconsequencesofalterationsinchloridetransportrequires
a detailed quantitative analysis of protein localization and
activity, a challenging task in this case, given that post-
mortem interval eﬀects alter the integrity of some of these
proteins [232].
Direct demonstration that GABA-mediated synaptic
inhibition is decreased in the cortex of subjects with
schizophrenia is challenging. Interestingly, magnetic reso-
nance spectroscopy (MRS) was recently applied to nonin-
vasively measured GABA concentration in human neocortex
and determined whether a decrease of GABA is observed in
schizophrenia. MRSdoes not distinguish extracellular GABA
from transmitter stored in particular cellular compartments
or cell types and also lacks adequate temporal resolution
butneverthelessrevealsactivity-dependentchangesinGABA
levels. For example, acute psychological stress which elevates
subjective anxiety produces a short-term decrease in GABA
concentration in human dorsolateral PFC that can be
detected with MRS [233]. Combining MRS and EEG in the
same subjects, the relations between brain GABA content
and oscillatory neural activity in schizophrenia may be
explored. Interestingly, in normal human subjects, GABA
concentration measured in visual cortex with MRS was
positively correlated with the strength of gamma oscillations
induced by visual stimulation [234]. Moreover, interindivid-
ual variation in GABA concentration determined by MRS in
visual cortex was correlated with variability of performance
in a visual stimulus orientation discrimination task that
induces gamma oscillations [235].
Measurements of tissue GABA concentration with MRS
may help in clarifying the relations between GAD67 lev-
els, gamma oscillations, and cognitive performance in
schizophrenia. One such study did not detect diﬀerences
in GABA concentration in the anterior cingulate cortex
of schizophrenia versus control subjects, whereas GABA
concentration was apparently decreased by antipsychotic
medications [236]. Another MRS study reported reduced
GABA concentration in basal ganglia but not frontal cortex
of schizophrenia patients [237]. In patients with relatively
low antipsychotic exposure, MRS revealed a signiﬁcant
reduction of GABA concentration in visual cortex that did
not covary with medication dosage but was correlated with
behavioral abnormalities in a visual surround-suppression
task thought to depend on GABA-mediated inhibition
[238]. Moreover, a longitudinal study of early-stage ﬁrst-
episode schizophrenia patients showed that 6 months of
treatment with atypical antipsychotics did not change GABA
concentrations measured with MRS in frontal and parietal
lobe cortices nor in basal ganglia [239]. In contrast, MRS
revealed elevated GABA concentration in anterior cingulate
and parietal cortex of subjects with chronically treated
schizophrenia compared to control subjects [240]. The MRS
ﬁndings suggesting that antipsychotics may change brain
GABA concentration highlight the importance of addressing
the eﬀects of confounding factors such as medications
[241].Signiﬁcantly,bothpostmortemstudiesinhumansand
experimental studies in animals have failed to show an eﬀect
of antipsychotic medications on GAD67 mRNA levels [224,
242, 243]. The data from MRS studies therefore underscore
the importance of combining neurochemical, electrophysio-
logical, and behavioral assessment, given the large interindi-
vidual variability in bulk GABA concentration, gamma
activity levels, and behavioral performance. Instead of or in
addition tomedication eﬀects,thelargevariability in cortical
GABA content measured with MRS in human cortex may be
explained by the eﬀects of genetic variants in the GAD1 gene
that may diﬀerentially confer risk of schizophrenia [244].
7. Conclusions
The ﬁndings reviewed here suggest that alterations of GABA
transmission produce cognitive deﬁcits in schizophrenia
by altering the circuit mechanisms of gamma oscillations.
These observations suggest a molecular and cellular basis
for the development of new therapeutic interventions [245].
Importantly, the proposal that GABA alterations are linked
to altered gamma oscillations and cognition is supported,
at least in part, by animal model studies showing that
producing a functional loss of GABA-mediated inhibition
diminishes gamma oscillations [246] and impairs cognitive
function [247, 248]. Whereas work in animal models is
essential, the diﬃculty of capturing in animals the complex-
ity of behavioral alterations in a uniquely human disorder
may explain the relative lack of success in developing drugs
to treat schizophrenia compared with other disease areas
[4, 5, 245]. Interpretation of studies in human subjects based
on comparisons between healthy controls and patients is
complicated as well, given that schizophrenia versus control
diﬀerences may actually reﬂect pathogenesis but also could
represent compensatory changes or eﬀects of confounding
factors [4, 241]. For example, the eﬀects of producingNeural Plasticity 15
a transient deﬁcit in GABAAR-mediated signaling were
tested recently in human subjects [249] using iomazenil, a
compoundthatbindstothebenzodiazepinesiteofGABAARs
andnegativelymodulatestheeﬀectsofGABA(i.e.,aninverse
agonist). Consistent with dysfunctional GABAAR signaling
in schizophrenia, iomazenil produced perceptual deﬁcits
and psychotic symptoms in schizophrenia patients at doses
that did not aﬀect healthy control subjects [249]. How-
ever, the schizophrenia patients in such study chronically
received antipsychotics and anxiolytics, raising the question
of whether an interaction between acute iomazenil and
chronic medications inﬂuenced such ﬁndings.
Preliminary tests of the idea that enhancing GABAAR
signaling improves behavioral and electrophysiological mea-
sures in subjects with schizophrenia were conducted in two
recent studies evaluating the eﬀects of MK-0777, an α2/α3
GABAAR-preferring positive allosteric modulator [47]. In
one study, randomized administration of MK-0777 or
placebo in double-blind fashion improved performance of
schizophrenia patients in a cognitive control task, simul-
taneously increasing gamma oscillation power in frontal
cortex [250]. In contrast, the second study did not ﬁnd
signiﬁcant eﬀects of MK-0777 compared with placebo in the
performanceofpatientsinabatteryoftestsdesignedtoassess
cognitive function in schizophrenia [251]. The inconsistent
beneﬁcial eﬀects of MK-0777 administration might be
explained by the fact that MK-0777 is a partial agonist at
α2/α3 subunit-containing GABAARs with only about 10–
20% potency compared to a full agonist [48]. Thus, one
possibilityisthatmorepotentα2/α3benzodiazepinesiteago-
nists need to be employed. Such drugs should also be more
selective because, compared with placebo, MK-0777 had a
tendency to produce sedation and somnolence [250, 251],
which could mask improvements in cognitive performance.
Importantly, the α2/α3 GABAAR modulator MK-0777 was
selected based on the compelling rationale that inputs
from PVChCs onto the AIS show important alterations in
schizophrenia [83] and that, depending on cortical layer,
such inputs involve α2-GABAARs or α3-GABAARs [101,
201, 252]. However, whether or not PVChCs play a role in
production of gamma band synchrony remains unclear [82],
and so it is possible that PVChC alterations in schizophrenia
produce cognitive deﬁcits unrelated to dysfunctional gamma
band synchrony. Therefore, further information from both
basic and clinical research studies is necessary to further
assess the eﬀectiveness of α2/α3 GABAAR modulators for
treatment of gamma synchrony-related cognitive deﬁcits
in schizophrenia. Indeed, basic research studies continue
to provide insight into the role of speciﬁc subtypes of
GABA neurons on inhibition-mediated cortical network
oscillations [127], and molecular pharmacology studies are
identifying novel compounds acting at diﬀerent sites within
the GABAARr e c e p t o rc o m p l e x[ 44, 47, 253].
Importantly, a potential role of GABA-mediated neural
synchrony in cortical circuits is to enable spike-timing-
dependent plasticity, indirectly modifying the strength and
stability of excitatory synaptic connections [254]. Whether
spike-timing-dependent plasticity at glutamate synapses is
impaired in schizophrenia is not yet clear [12], but it is
possible that the decrease of dendritic spine density in pyra-
midal neurons in schizophrenia is due to glutamate synapse
loss produced by altered plasticity mechanisms [241]. If
neural synchrony-dependent glutamate synaptic plasticity
is dysfunctional in schizophrenia, then cognitive enhance-
ment behavioral therapies that involve learning paradigms
may help in preventing or reversing the consequences of
altered circuitry on the induction of synaptic plasticity.
Interestingly, cognitive enhancement behavioral therapy was
recently shown to improve cognition and prevent gray
matter loss in schizophrenia [255]. Potentially, combining
cognitive therapies with pharmacological treatment that
boosts otherwise weakened neural synchrony may constitute
an eﬀective treatment intervention in schizophrenia, as for
other psychiatric disorders [256].
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